4.8 Article

Design and synthesis of a novel mitochondria-targeted osteosarcoma theranostic agent based on a PIM1 kinase inhibitor

Journal

JOURNAL OF CONTROLLED RELEASE
Volume 332, Issue -, Pages 434-447

Publisher

ELSEVIER
DOI: 10.1016/j.jconrel.2021.02.028

Keywords

PIM1; Kinase inhibitor; Osteosarcoma; Near-infrared imaging; Anti-tumor

Funding

  1. Hubei Province Scientific and Technical Innovation Key Project [2019ACA136]
  2. Interdisciplinary Project of Wuhan University [2042018kf0216]
  3. National Natural Science Foundation of China [82073808]
  4. Wuhan Young & Middle-aged Medical Backbone Training Program

Ask authors/readers for more resources

Osteosarcoma is a common malignancy of the skeletal system with poor prognosis and high recurrence rates. The overexpression of PIM1 kinase in OS has been targeted for the development of a novel near-infrared imaging and targeted therapeutic agent, QCAiCy7d, which showed promising results in vitro and vivo. This new conjugate has potential for precise tumor imaging and targeted treatment.
Osteosarcoma (OS) is the most common malignancy of the skeletal system, with a poor prognosis and high rate of recurrence. Adequate surgical margin and adjuvant chemotherapy improve the overall survival and limb salvage rate of osteosarcoma patients. Previous studies have showed that OS exhibits an increase in the expression of proviral integration site for Moloney murine leukemia virus 1 (PIM1) kinase, and high levels of PIM1 are also associated with poor OS prognosis and metastasis. We exploited the overexpression of proto-oncogenic PIM1 in OS towards the development of a novel near-infrared imaging and targeted therapeutic agent, namely QCAiCy7d by conjugating a PIM1 small molecule inhibitor and heptamethine cyanine dye, for simultaneous guiding surgery and chemotherapy. QCAi-Cy7d showed targeted imaging and anticancer activities against OS in vitro and vivo without any obvious toxicity, and its antitumoral activity was much greater than the parent PIMI inhibitor. These results demonstrated the potential of new conjugate of PIM1 inhibitor and near-infrared imaging, supporting structure-based design and development of theranostic agents for precise tumor imaging and targeted treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available